Literature DB >> 6128041

The cardiovascular effects of ICI 118,587: A beta 1-adrenoceptor partial agonist.

A Nuttall, H M Snow.   

Abstract

1 In a preparation in which cardiovascular reflexes were prevented from occurring, ICI 118,587 (1-(p-hydroxyphenoxy)-3-beta-(morpholinocarbonamido) ethylamino-2-propranol fumarate) caused dose-dependent positive chronotropic and inotropic effects upon the dog heart. 2 The increase in heart rate brought about by ICI 118,587 was about 43% of the maximum increase produced by isoprenaline. 3 For a given chronotropic effect produced by either ICI 118,587 or isoprenaline, each compound produced a similar inotropic effect as indicated by an increase in LV dp/dtmax. 4 In contrast to the direct stimulant action of ICI 118,587 on the heart no direct effects on vascular smooth muscle were observed. 5 ICI 118,587 was shown to be a competitive antagonist of the chronotropic and vasodilator effects of isoprenaline on the heart and blood vessels and of the chronotropic effects of noradrenaline on the heart. 6 It is concluded that ICI 118,587 is a selective beta 1-adrenoceptor partial agonist.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6128041      PMCID: PMC2044596          DOI: 10.1111/j.1476-5381.1982.tb09309.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  10 in total

1.  Circulatory, respiratory and metabolic responses to isopropylnoradrenaline in man.

Authors:  A F COBBOLD; J GINSBURG; A PATON
Journal:  J Physiol       Date:  1960-06       Impact factor: 5.182

2.  In vivo analysis of adrenergic receptor activity of dobutamine.

Authors:  N W Robie; D O Nutter; C Moody; J L McNay
Journal:  Circ Res       Date:  1974-05       Impact factor: 17.367

3.  Action of propranolol on the dog heart.

Authors:  J D Harry; C T Kappagoda; R J Linden; H M Snow
Journal:  Cardiovasc Res       Date:  1973-11       Impact factor: 10.787

4.  Assessment of cardiac contractility. The relation between the rate of pressure rise and ventricular pressure during isovolumic systole.

Authors:  D T Mason; E Braunwald; J W Covell; E H Sonnenblick; J Ross
Journal:  Circulation       Date:  1971-07       Impact factor: 29.690

5.  The cardiovascular acitivity of ICI 118,587 a novel beta-adrenoceptor partial agonist [proceedings].

Authors:  J J Barlow; B D Main; J A Moors; A Nuttall; H M Snow
Journal:  Br J Pharmacol       Date:  1979-11       Impact factor: 8.739

6.  A study of the relationship between cardiac beta-adrenoceptor blockade and intrinsic sympathomimetic activity in rats depleted of catecholamines.

Authors:  A Bilski; H H Robertson; J L Wale
Journal:  Clin Exp Pharmacol Physiol       Date:  1979 Jan-Feb       Impact factor: 2.557

7.  Inotropic changes in the left ventricle: the effect of changes in heart rate, aortic pressure and end-diastolic pressure.

Authors:  C M Furnival; R J Linden; H M Snow
Journal:  J Physiol       Date:  1970-12       Impact factor: 5.182

8.  Beta-adrenoceptor stimulant properties of amidoalkylamino-substituted 1-aryl-2-ethanols and 1-(aryloxy)-2-propanols.

Authors:  J J Barlow; B G Main; H M Snow
Journal:  J Med Chem       Date:  1981-03       Impact factor: 7.446

9.  Inotropic and chronotropic responses of the in vivo denervated dog myocardium to dobutamine.

Authors:  C P Bolter; J R Ledsome
Journal:  Can J Physiol Pharmacol       Date:  1976-08       Impact factor: 2.273

10.  The inotropic and chronotropic effects of catecholamines on the dog heart.

Authors:  C M Furnival; R J Linden; H M Snow
Journal:  J Physiol       Date:  1971-04       Impact factor: 5.182

  10 in total
  51 in total

1.  The cardiovascular effects of xamoterol, a beta 1-adrenoceptor partial agonist, in healthy volunteers at rest.

Authors:  T Hashimoto; A Shiina; T Toyo-Oka; S Hosoda; K Kondo
Journal:  Br J Clin Pharmacol       Date:  1986-03       Impact factor: 4.335

2.  Ischaemic left ventricular failure: evidence of sustained benefit after 18 months' treatment with xamoterol.

Authors:  E Vigholt-Sørensen; O Faergeman
Journal:  Br Heart J       Date:  1990-09

Review 3.  Beta-adrenoceptor partial agonists: a renaissance in cardiovascular therapy?

Authors:  D G Waller
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

4.  Pharmacokinetics of xamoterol after intravenous and oral administration to patients with chronic heart failure.

Authors:  E V Sorensen; O Faergeman; M Day; W Bastain
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 5.  Xamoterol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  R Furlong; R N Brogden
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

6.  Comparison of the effects of xamoterol and isoprenaline on rat cardiac beta-adrenoceptors: studies of function and regulation.

Authors:  M T Kowalski; D Haworth; X Lu; D S Thomson; D B Barnett
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

Review 7.  Myocardial beta-adrenoceptor function and regulation in heart failure: implications for therapy.

Authors:  D B Barnett
Journal:  Br J Clin Pharmacol       Date:  1989-05       Impact factor: 4.335

8.  The in vitro pharmacology of xamoterol (ICI 118,587).

Authors:  E Malta; M A Mian; C Raper
Journal:  Br J Pharmacol       Date:  1985-05       Impact factor: 8.739

9.  Renal effects of xamoterol in patients with moderate heart failure.

Authors:  H E Bøtker; H K Jensen; L R Krusell; E V Sørensen
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

Review 10.  Inotropic support of the critically ill patient. A review of the agents.

Authors:  P J Kulka; M Tryba
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.